TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32502588

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5%
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1%
Number of subjects: 247

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5% once daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5% twice daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% twice daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5% once or twice daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: All tapinarof groups
Number of subjects: 247
Study: 34216454

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with epinephrine (40 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine 2% with epinephrine (20 ml)
Number of subjects: 20
Study: 33742536

Group type: EXPERIMENTAL
Intervention: Satisfaction with social roles
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Anxiety symptoms
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Manic symptoms
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Emotion-focused positive rumination
Number of subjects: 209
Study: 36307989

Group type: EXPERIMENTAL
Intervention: Topical gentamicin cream delivered via the platform wound device (PWD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC) dressings
Number of subjects: 0
Study: 36266111

Group type: EXPERIMENTAL
Intervention: Mobile emergency medical dispatch tool
Number of subjects: 10
Study: 33334938

Group type: EXPERIMENTAL
Intervention: Ambulatory care with a flutter valve (Pleural Vent or Atrium Pneumostat)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard care with chest tube and underwater seal
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ambulatory care with Pleural Vent (PV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ambulatory care with Atrium Pneumostat (AP)
Number of subjects: 41
Study: 36153456

Group type: EXPERIMENTAL
Intervention: Medication + Thunder-fire moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 60
Study: 32749999

Group type: EXPERIMENTAL
Intervention: Web-based assessment using CANTAB
Number of subjects: 51

Group type: COMPARATOR
Intervention: Lab-based assessment using CANTAB
Number of subjects: 51
Study: 33278290

Group type: EXPERIMENTAL
Intervention: Digital placement of a balloon catheter
Number of subjects: 372

Group type: COMPARATOR
Intervention: Sterile speculum method
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 372

Group type: COMPARATOR
Intervention: Sterile speculum group
Number of subjects: 372
Study: 33401330

Group type: EXPERIMENTAL
Intervention: Prasugrel standard-dose (10 mg)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Prasugrel de-escalation strategy (5 mg and PFT-guided)
Number of subjects: 255
Study: 33327696

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 80

Group type: COMPARATOR
Intervention: Baska mask
Number of subjects: 80
Study: 35612640

Group type: EXPERIMENTAL
Intervention: Supported Employment Intervention (IPS-MA)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 289
Study: 33627776

Group type: EXPERIMENTAL
Intervention: Prenatal intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 264
Study: 34789277

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-directed condition (receipt of information on TASSH without PF)
Number of subjects: 30
Study: 35618611

Group type: EXPERIMENTAL
Intervention: Family-based participatory care program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Increased family participation (control group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 90
Study: 33646192

Group type: EXPERIMENTAL
Intervention: DEBISim software simulation pipeline
Number of subjects: 0
Study: 35958679

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg esketamine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 105
Study: 33653326

Group type: EXPERIMENTAL
Intervention: i-PRF
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no i-PRF)
Number of subjects: 21
Study: 32653539

Group type: EXPERIMENTAL
Intervention: Text Messaging (TM)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EC)
Number of subjects: 646
Study: 35947894

Group type: EXPERIMENTAL
Intervention: Calorie Restriction Interventions (CRI)
Number of subjects: 3037

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 3037

Group type: EXPERIMENTAL
Intervention: Dietary Interventions (including both CRI and MD)
Number of subjects: 3037
Study: 33352584

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (8 IU, self-administered up to thrice daily for 4 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 32814684

Group type: EXPERIMENTAL
Intervention: nGBE (Ginkgo biloba extract with pinitol)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tGBE (traditional Ginkgo biloba extract without pinitol)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: pinitol alone
Number of subjects: 100
Study: 33125189

Group type: EXPERIMENTAL
Intervention: MK-1654 (100 mg, 300 mg intramuscular; 300 mg, 1000 mg, 3000 mg intravenous)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 32533791

Group type: EXPERIMENTAL
Intervention: 2 mg.kg‐1 intranasal dexmedetomidine
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 intravenous dexmedetomidine
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 247
Study: 35941557

Group type: EXPERIMENTAL
Intervention: Transdiagnostic guided internet-delivered intervention with synchronous assistance
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Transdiagnostic self-guided internet-delivered intervention
Number of subjects: 207

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 207
Study: 34016947

Group type: EXPERIMENTAL
Intervention: Probiotics (EcologicBarrier consisting of Lactobacilli, Lactococci, and Bifidobacteria)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Probiotics (EcologicBarrier)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 35278766

Group type: EXPERIMENTAL
Intervention: dinutuximab/irinotecan
Number of subjects: 471

Group type: COMPARATOR
Intervention: irinotecan
Number of subjects: 471

Group type: COMPARATOR
Intervention: topotecan
Number of subjects: 471
Study: 32325919

Group type: EXPERIMENTAL
Intervention: Low Fructose Diet (LFD)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Standard Diet (SD)
Number of subjects: 438
Study: 36254906

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae plane block (ESPB)
Number of subjects: 0
Study: 33837987

Group type: EXPERIMENTAL
Intervention: FFR-guided strategy
Number of subjects: 172
Study: 32166864

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 36274185

Group type: EXPERIMENTAL
Intervention: CBTv-based EMI in addition to treatment as usual (TAU)
Number of subjects: 154

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 154
Study: 33907787

Group type: EXPERIMENTAL
Intervention: Aiweizhi (experimental group)
Number of subjects: 113

Group type: COMPARATOR
Intervention: New rehabilitation (control group)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study: 33394323

Group type: EXPERIMENTAL
Intervention: Solriamfetol treatment for 12 weeks
Number of subjects: 690
Study: 34981428

Group type: EXPERIMENTAL
Intervention: Glucose loading
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 33
Study: 33271000

Group type: EXPERIMENTAL
Intervention: Informed consent obtained
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Specific waivers for inclusion
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Willingness to participate statement
Number of subjects: 368

Group type: COMPARATOR
Intervention: Consent refusal rates
Number of subjects: 368
Study: 35120890

Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE) at 300 μg PM2.5/m3 for 2 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE) at 20, 50, or 150 μg PM2.5/m3 for 4 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 17
Study: 35708845

Group type: EXPERIMENTAL
Intervention: High SBP (≥ 140 mm Hg)
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Moderate SBP (140 > SBP ≥ 130 mm Hg)
Number of subjects: 2509

Group type: COMPARATOR
Intervention: Low SBP (< 130 mm Hg)
Number of subjects: 2509
Study: 34390283

Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sham Acupuncture (SA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 75
Study: 32252963

Group type: EXPERIMENTAL
Intervention: TTNS sensitivity threshold (n=39)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: TTNS motor threshold (n=33)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (n=29)
Number of subjects: 101
Study: 35051725

Group type: EXPERIMENTAL
Intervention: Cisplatin-gemcitabine (CG) followed by gemcitabine (G) maintenance for patients with objective response (OR) or switch to pemetrexed (P) for patients with stable disease (SD)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Control arm: 4 cycles of cisplatin-pemetrexed (CP) followed by pemetrexed (P) maintenance
Number of subjects: 932
Study: 34210203

Group type: EXPERIMENTAL
Intervention: Flushing at 6°C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flushing at 23°C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flushing at 40°C
Number of subjects: 60
Study: 33036728

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 0
Study: 36101997

Group type: EXPERIMENTAL
Intervention: Rutin 500 mg per day for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33884889

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I ≥5 ng/L
Number of subjects: 15833

Group type: EXPERIMENTAL
Intervention: BNP ≥100 pg/mL
Number of subjects: 15833

Group type: EXPERIMENTAL
Intervention: Combination of high-sensitivity cardiac troponin I ≥5 ng/L and BNP ≥100 pg/mL
Number of subjects: 15833

Group type: EXPERIMENTAL
Intervention: BNP in multivariable Cox regression model
Number of subjects: 15833

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I in multivariable Cox regression model
Number of subjects: 15833
Study: 36058687

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 42
Study: 32050215

Group type: EXPERIMENTAL
Intervention: 105 nJ
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 110 nJ
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 115 nJ
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 120 nJ
Number of subjects: 62
Study: 35599469

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (3 times a week for 6 weeks, 60 minutes per session)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 34902841

Group type: EXPERIMENTAL
Intervention: Eccentric hamstring strength training program (EHT) performed 2 days per week for 6 weeks, consisting of 5 exercises
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study: 34263472

Group type: EXPERIMENTAL
Intervention: Edasalonexent (100 mg or 250 mg softgel capsules)
Number of subjects: 181
Study: 33449508

Group type: EXPERIMENTAL
Intervention: DLPFC-tDCS
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: M1-tDCS
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: DLPFC&M1-tDCS
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: All active HD-tDCS protocols
Number of subjects: 81
Study: 33637541

Group type: EXPERIMENTAL
Intervention: iACT intervention group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 200
Study: 32651292

Group type: EXPERIMENTAL
Intervention: 200/50 mg dispersible levodopa‐benserazide (dopaminergic challenge)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (double-blinded, placebo-controlled dopaminergic challenge)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Repeated levodopa challenge after 6 months
Number of subjects: 76
Study: 36414584

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both Methotrexate and Azathioprine
Number of subjects: 100
Study: 32317575

Group type: EXPERIMENTAL
Intervention: Prehospital plasma
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Severe hypocalcemia
Number of subjects: 160
Study: 616683537

Group type: EXPERIMENTAL
Intervention: Microneedling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microdermabrasion
Number of subjects: 30
Study: 34210824

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target 110-139 mm Hg)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Standard blood pressure control (target 140-179 mm Hg)
Number of subjects: 974
Study: 616689159

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (specifics not provided)
Number of subjects: 30
Study: 33961204

Group type: EXPERIMENTAL
Intervention: JiTT screencasts
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual education curriculum
Number of subjects: 67
Study: 33057184

Group type: EXPERIMENTAL
Intervention: Early promotion group (encouraged to visit a clinic in face-to-face interviews, provided with a referral letter and leaflet)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (received usual care)
Number of subjects: 273
Study: 616122532

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 24
Study: 35942688

Group type: EXPERIMENTAL
Intervention: 1% sodium gluconate
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 50
Study: 33967000

Group type: EXPERIMENTAL
Intervention: Tampon test
Number of subjects: 10
Study: 32826786

Group type: EXPERIMENTAL
Intervention: Repeat pars‐plana vitrectomy (PPV) and gas tamponade with ILM peel extension in 20 cases
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Repeat pars‐plana vitrectomy (PPV) and gas tamponade
Number of subjects: 27
Study: 35285804

Group type: EXPERIMENTAL
Intervention: Supraflex sirolimus-eluting stent
Number of subjects: 1435

Group type: COMPARATOR
Intervention: XIENCE everolimus-eluting stent
Number of subjects: 1435
Study: 33137486

Group type: EXPERIMENTAL
Intervention: MAFLD diagnosed as intrahepatic triglyceride content (IHTG) ≥5% and presence of overweight/obesity, diabetes, or two other metabolic risk factors.
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: NAFLD diagnosed with exclusion of concomitant liver diseases; metabolic factors not considered.
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: MAFLD incidence.
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Subjects with incident NAFLD.
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Subjects with IHTG ≥5% but did not meet the metabolic criteria of MAFLD.
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Regular drinker with liver stiffness.
Number of subjects: 1013
Study: 32434296

Group type: EXPERIMENTAL
Intervention: Single-hole thoracoscopic surgery with ERAS concept education and respiratory function training (Group A)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional 3-hole thoracoscopic surgery with ERAS concept education and respiratory function training (Group B)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional 3-hole thoracoscopic surgery with routine hospitalization education and nursing guidance (Group C)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Single-hole thoracoscopic surgery with routine hospitalization education and nursing guidance (Group D)
Number of subjects: 240
Study: 34346173

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surrogate outcome (time to metastasis)
Number of subjects: 0
Study: 33342941

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 254
Study: 35665787

Group type: EXPERIMENTAL
Intervention: h-SDS micelles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-SDS micelles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: h-SDS and d-SDS micelles
Number of subjects: 0
Study: 34613617

Group type: EXPERIMENTAL
Intervention: ENABLE intervention (palliative care intervention)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Usual care (control group in ENABLE II)
Number of subjects: 529
Study: 33734288

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study: 32812041

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 469
Study: 616852914

Group type: EXPERIMENTAL
Intervention: Novel disposable circumcision stitching instrument
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional circumcision operation
Number of subjects: 102
Study: 34464634

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 33813324

Group type: EXPERIMENTAL
Intervention: 0.90% Ca
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: 0.35% NPP
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: 0.80% Ca
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: 0.30% NPP
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Interaction of Ca and NPP
Number of subjects: 720
Study: 35770887

Group type: EXPERIMENTAL
Intervention: The App (Stroke Riskometer™ mobile phone application)
Number of subjects: 790

Group type: COMPARATOR
Intervention: Usual care (generic online information about risk factors)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: The App
Number of subjects: 790
Study: 34071171

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (individual, group, and community interventions for 12 months)
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 694

Group type: COMPARATOR
Intervention: Usual health care (Control)
Number of subjects: 694
Study: 35074896

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32272249

Group type: EXPERIMENTAL
Intervention: Reflux hypersensitivity (RH) with excessive supragastric belching (SGB)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Reflux hypersensitivity (RH) with rumination
Number of subjects: 542

Group type: COMPARATOR
Intervention: Functional heartburn
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Reflux hypersensitivity (RH)
Number of subjects: 542
Study: 35745216

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet group weaned with fresh, seasonal, and tasty foods of Med Diet
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control group predominantly weaned with industrial baby foods
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet group
Number of subjects: 394
Study: 33706344

Group type: EXPERIMENTAL
Intervention: Superior hypogastric plexus block
Number of subjects: 100

Group type: COMPARATOR
Intervention: No superior hypogastric plexus block (Control)
Number of subjects: 100
Study: 32119599

Group type: COMPARATOR
Intervention: C-IMRT (76 Gy in 38 fractions)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: H-IMRT (70.2 Gy in 26 fractions)
Number of subjects: 303

Group type: COMPARATOR
Intervention: C-IMRT
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: H-IMRT
Number of subjects: 303
Study: 36250812

Group type: EXPERIMENTAL
Intervention: Increased amputated-region sensitivity (n = 24)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Non-sensitive group (n = 36)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Overall participants with central sensitization symptoms
Number of subjects: 99
Study: 32604068

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 101
Study: 37385337

Group type: EXPERIMENTAL
Intervention: Home spirometry
Number of subjects: 2857

Group type: COMPARATOR
Intervention: Clinic spirometry
Number of subjects: 2857
Study: 33484254

Group type: EXPERIMENTAL
Intervention: Exercise and Protein (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Protein (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Group D)
Number of subjects: 60
Study: 32312255

Group type: EXPERIMENTAL
Intervention: 3-month course with the self-management package and a support session
Number of subjects: 50
Study: 34009514

Group type: EXPERIMENTAL
Intervention: Magnesium and Melatonin co-supplementation for 8 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Melatonin for 8 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Magnesium plus Melatonin for 8 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 84